The death panel for Charcot-Marie-Tooth panels

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 1-4

  Amato, Anthony A ^a   Reilly, Mary M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CLASSIFICATION; DISEASE SEVERITY; GENE LOCATION; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INHERITANCE; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

CHARCOT-MARIE-TOOTH DISEASE; CHROMOSOME MAPPING; GENETIC TESTING; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIAL PROTEINS; MUTATION; MYELIN PROTEINS;

EID: 79551474508     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22272     Document Type: Review

References (5)

1. Amato AA, Russell J., Neuromuscular disease. New York, NY: McGraw-Hill, 2008.
2. England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 2009; 39: 116-125.
3. Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth subtypes and genetic testing strategies. Ann Neurol 2011; 69: 22-33.
4. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008; 70: 378-383.
5. Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68: 849-855.